Iradimed Corp (NASDAQ:IRMD) VP Sells $65,490.00 in Stock

Iradimed Corp (NASDAQ:IRMD) VP Brent Johnson sold 3,000 shares of the company’s stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $21.83, for a total value of $65,490.00. Following the sale, the vice president now owns 4,368 shares of the company’s stock, valued at $95,353.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Brent Johnson also recently made the following trade(s):

  • On Monday, June 10th, Brent Johnson sold 1,000 shares of Iradimed stock. The shares were sold at an average price of $20.06, for a total value of $20,060.00.
  • On Wednesday, June 12th, Brent Johnson sold 3,000 shares of Iradimed stock. The shares were sold at an average price of $20.57, for a total value of $61,710.00.
  • On Friday, June 7th, Brent Johnson sold 1,000 shares of Iradimed stock. The shares were sold at an average price of $20.00, for a total value of $20,000.00.
  • On Thursday, May 23rd, Brent Johnson sold 4,000 shares of Iradimed stock. The shares were sold at an average price of $21.78, for a total value of $87,120.00.
  • On Monday, May 20th, Brent Johnson sold 2,000 shares of Iradimed stock. The shares were sold at an average price of $22.53, for a total value of $45,060.00.
  • On Wednesday, March 13th, Brent Johnson sold 52,492 shares of Iradimed stock. The shares were sold at an average price of $24.42, for a total value of $1,281,854.64.
  • On Monday, March 11th, Brent Johnson sold 17,033 shares of Iradimed stock. The stock was sold at an average price of $25.38, for a total value of $432,297.54.
  • On Wednesday, March 6th, Brent Johnson sold 9,672 shares of Iradimed stock. The shares were sold at an average price of $24.58, for a total value of $237,737.76.

Shares of Iradimed stock opened at $20.98 on Thursday. The firm has a market capitalization of $233.63 million, a PE ratio of 48.79 and a beta of 1.78. The company has a quick ratio of 8.63, a current ratio of 9.48 and a debt-to-equity ratio of 0.06. Iradimed Corp has a 12 month low of $18.40 and a 12 month high of $38.78.

Iradimed (NASDAQ:IRMD) last released its quarterly earnings data on Tuesday, April 30th. The medical equipment provider reported $0.11 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.11. Iradimed had a return on equity of 13.98% and a net margin of 23.00%. The firm had revenue of $8.44 million during the quarter, compared to analysts’ expectations of $8.38 million. As a group, analysts predict that Iradimed Corp will post 0.64 earnings per share for the current fiscal year.

Several equities analysts have recently issued reports on IRMD shares. BidaskClub upgraded Iradimed from a “hold” rating to a “buy” rating in a research report on Friday, April 26th. ValuEngine cut Iradimed from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. Finally, Zacks Investment Research upgraded Iradimed from a “hold” rating to a “buy” rating and set a $28.00 price target on the stock in a research report on Tuesday, May 7th. Two investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $31.50.

Institutional investors have recently bought and sold shares of the company. Ruggie Capital Group acquired a new stake in Iradimed during the fourth quarter worth about $34,000. Barclays PLC boosted its holdings in Iradimed by 53.9% during the fourth quarter. Barclays PLC now owns 2,059 shares of the medical equipment provider’s stock valued at $50,000 after purchasing an additional 721 shares in the last quarter. Oppenheimer Asset Management Inc. acquired a new stake in Iradimed during the first quarter valued at approximately $76,000. Nkcfo LLC acquired a new position in shares of Iradimed in the 4th quarter worth approximately $87,000. Finally, Teachers Advisors LLC bought a new position in Iradimed in the 3rd quarter worth approximately $261,000. Institutional investors and hedge funds own 23.53% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Iradimed Corp (NASDAQ:IRMD) VP Sells $65,490.00 in Stock” was reported by Riverton Roll and is the sole property of of Riverton Roll. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://rivertonroll.com/news/2019/06/13/iradimed-corp-irmd-vp-sells-65490-00-in-stock.html.

Iradimed Company Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system.

Featured Article: What is a blue-chip stock?

Insider Buying and Selling by Quarter for Iradimed (NASDAQ:IRMD)

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.